Ind-Swift Laboratories share news and announcements
NSE: INDSWFTLABBSE: 532305Pharmaceuticals & BiotechnologySmall Cap
Last close ₹327.45down ₹17.90 (5.18%)BSE ₹327.80
Share price at the NSE close on 23 Oct 2026. Previous close ₹345.35.
52-week range of traded prices to 23 Oct 2026
₹87.15Low, 31 Dec 2025₹424.75High, 30 Sep 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 29 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,848 Cr1,404th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 49.7
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹11 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 41.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 28 May 2026
- 2.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 4.5%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹11 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 5.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 2.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 28 May 2026
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 6,58,24852.8% delivered
Ind-Swift Laboratories board and management
39 filed, newest first.
Jun 2026
22 Jun · Management
22 Jun · Management
Dec 2025
Jul 2025
4 Jul · Management
May 2025
30 May · Management
Feb 2025
Aug 2024
12 Aug · Management
6 Aug · Management
Mar 2024
18 Mar · Management
Oct 2022
Aug 2022
Jun 2021
23 Jun · Management
Apr 2021
May 2019
10 May · Management
Oct 2018
Sep 2018
Jun 2018
14 Jun · Management
May 2018
Apr 2017
Sep 2016
Mar 2015
Jan 2015
Nov 2014
7 Nov · Management
Resignations of Sh T. S. Bhattacharya and Dr. Vinay Kumar Arora from the Directorship of the Company.
Apr 2014
Apr 2013
10 Apr · Management
Shri R. K. Ummat has been appointed as an Independent Director on the Board of the Company.
Mar 2013
13 Mar · Management
Shri. Atul Saxena has ceased to be a Nominee Director on the Board of Directors of the Company pursuant to withdrawal of nomination by IFCI w.e.f. February 19, 2013.
Oct 2010
1 Oct · Management
Board of Directors have appointed Dr. N.P. Singh as Independent Director with immediate effect.
Mar 2010
23 Mar · Management
Ind-Swift Laboratories Ltd. has informed the Exchange that the Board of Directors of the Company met on March 23, 2010, the board have approved the following:(1) Appointment of Sh. N. R. Munjal as the Vice Chairman cum Managing Director of the Company, (2) Appointment of Sh. Himanshu Jain, Director as the Joint Managing Director of the Company, (3) Appointment of Mr. Rishav Mehta S/o Late Sh. V. K. Mehta as the Director of the Company, (4) Appointment of Sh. Pradeep Kumar as an Independent Director on the Board of the Company, (5) Appointment of Dr. L. K. Wadhwa as the Chief Operating Officer (COO). The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2009
26 Mar · Management
Ind-Swift Laboratories Ltd. has informed the Exchange that pursuant to Clause 30 and Clause 49 (A)(ii) the Listing Agreement, the Board of Directors of the Company in its meeting held on March 24, 2009 have appointed the following as Independent Directors with immediate effect: 1) Mr. H.P.S.Chawla, 2) Mr. N.D.Aggarwal, 3) Mrs.Nirmal Aggarwal.